Interview with Dr. Mischel from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance

Abstract

<p>mp3 file (9.8 MB). In the November edition of the Cancer Discovery podcast, Executive Editor Mark Landis talks with Paul S. Mischel about his paper, which identifies mTORC2 as a novel mediator of drug resistance and regulator of NF-κB signaling in glioblastoma.</p>